Search
Close this search box.

madmin

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM,

Read More

Kenya Launches Innovative Lung Cancer Therapy

The Ministry of Health, in partnership with AstraZeneca, the Kenya Society of Haematology (KESHO), Axios, the National Cancer Institute of Kenya (NCI), various health facilities, and professional societies, has recently launched an innovative therapy …

Read More

Pages